%0 Journal Article
%T 靶向SOS1的抗肿瘤小分子抑制剂研究进展<br>Research Progress of Antitumor Small Molecule Inhibitor Targeting SOS1
%A 黄景坤
%A 王卉
%A 朱雍
%J World Journal of Cancer Research
%P 97-105
%@ 2164-9057
%D 2023
%I Hans Publishing
%R 10.12677/WJCR.2023.132014
%X 大鼠肉瘤(rat sarcoma, RAS)是人类癌症中最常发生突变的癌基因，约占所有人类癌症突变的30%。RAS基因与胞内多条控制增殖、分化等生理过程的通路相关。SOS1 (son of sevenless 1)作为RAS信号通路中的中心节点，可通过蛋白–蛋白相互作用激活RAS蛋白，因此SOS1小分子抑制剂为治疗RAS依赖性癌症提供机遇。最近一些文献和专利文件已经证明了其治疗RAS突变驱动型癌症的潜力，通过对SOS1蛋白及其小分子抑制剂进行总结，为其进一步研究和应用提供参考。<br />
Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, accounting for approximately 30% of all human cancer mutations. RAS gene is associated with several intracellular pathways which control proliferation, differentiation and other physiological processes. As a central node in RAS signaling pathway, SOS1 (son of sevenless 1) can activate RAS proteins through protein-protein interaction, thus explaining that SOS1 small molecule inhibitors offer an opportunity to treat RAS-dependent cancers. Its potential in the treatment of RAS mutation-driven cancers has been demonstrated in recent literature and patent documents, and the structure and indications of these SOS1 small molecule inhibitors are summarized to provide reference for further research and application.
%K SOS1，RAS，抗肿瘤，抑制剂<br>SOS1
%K RAS
%K Anti-Cancer
%K Inhibitor
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64832